Newman Lisa A, Singletary S Eva
Breast Care Center, 1500 East Medical Center Drive, 3308 CGC, University of Michigan, Ann Arbor, MI 48109, USA.
Surg Clin North Am. 2007 Apr;87(2):499-509, xi. doi: 10.1016/j.suc.2007.01.002.
The benefits of adjuvant systemic therapy in reducing risk of distant relapse from breast cancer have been recognized for several decades. The intent of adjuvant therapy is to eliminate the occult micrometastatic breast cancer burden before it progresses into clinically apparent disease. Successful delivery of effective adjuvant systemic therapy as a complement to surgical management of breast cancer has contributed to the steady declines in breast cancer mortality observed internationally over the past 2 decades. Ongoing clinical and translational research in breast cancer seeks to improve the efficacy of systemic agents for use in the conventional postoperative (adjuvant) setting.
辅助性全身治疗在降低乳腺癌远处复发风险方面的益处已被认可数十年。辅助治疗的目的是在隐匿性微转移乳腺癌进展为临床显性疾病之前消除其负担。成功实施有效的辅助性全身治疗作为乳腺癌手术治疗的补充，促成了过去20年里在国际上观察到的乳腺癌死亡率的稳步下降。正在进行的乳腺癌临床和转化研究旨在提高全身药物在传统术后（辅助）治疗中的疗效。
